Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:58 PM
Ignite Modification Date:
2025-12-24 @ 5:58 PM
NCT ID:
NCT02304068
Eligibility Criteria:
Inclusion Criteria:
* Patients over 60 years with a clinical diagnosis of neovascular age-related macular degeneration (ARMD), receiving treatment with intra-vitreal ranibizumab in accordance with current UK practice
* At least 6 months of prior treatment beyond the loading phase of three fixed injections
* At least 2 injections during the prior 6 months of the maintenance phase of treatment
* Early Treatment for Diabetic Retinopathy Study (ETDRS) chart letter score at 2m of between 30 and 70 letters at the start of the study
Exclusion Criteria:
* Patients with chronic intra-retinal cycts or sub-retinal fluid in the study eye on Optical coherence tomography (OCT) examination despite prior treatment and judged to be stable without the need for further treatment
* Significant hearing impairment, felt likely to interfere with training and the telephone calls prior to the home monitoring
* Lack of informed consent
Sex:
ALL
Minimum Age:
60 Years
Maximum Age:
99 Years
Study:
NCT02304068
Study Brief:
Protocol Section:
NCT02304068